Perjeta Panel Review Could Pave Way For Neoadjuvant Approvals
This article was originally published in The Pink Sheet Daily
Executive Summary
The September advisory committee review of Roche’s sBLA for Perjeta will be the first test of the agency’s guidance on using accelerated approval for neoadjuvant breast cancer.